SHANGHAI, CHINA--(Marketwire - October 02, 2007) - Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to announce that its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”), has been designated as a “High and New Technology Enterprise” by the Science and Technology Commission of the Municipality of Shanghai in accordance with standards set by the Chinese Ministry of Science and Technology.
